A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours

Summary

This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.

Timeline

Start

2026-05-25

Primary completion

2027-06-29

Completion

2028-05-24

Drugs

Indications